Comparative Pharmacology
Head-to-head clinical analysis: ATRIDOX versus BRISTACYCLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATRIDOX versus BRISTACYCLINE.
ATRIDOX vs BRISTACYCLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATRIDOX (doxycycline hyclate) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases (MMPs) and reducing cytokine production.
BRISTACYCLINE is a tetracycline antibiotic that reversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
50 mg subgingival controlled-release insert applied by dental professional into periodontal pockets once every 3 months.
250 mg orally every 6 hours for 7-14 days.
None Documented
None Documented
Terminal half-life 16-18 hours; prolonged to 24-48 hours in renal impairment, requiring dose adjustment.
6-12 hours (terminal). In renal impairment, half-life extends up to 24-48 hours; dose adjustment required for CrCl <30 mL/min.
Primarily renal (60-70% unchanged), biliary/fecal (10-15%) as active drug and metabolites; remainder metabolized.
Renal (40-60% unchanged), fecal (20-30%, primarily as inactive metabolites). Biliary excretion contributes minimally (<5%).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic